tiprankstipranks
Trending News
More News >
Addex Therapeutics (ADXN)
NASDAQ:ADXN
US Market
Advertisement

Addex Therapeutics (ADXN) Earnings Dates, Call Summary & Reports

Compare
80 Followers

Earnings Data

Report Date
Nov 10, 2025
TBA (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
Last Year’s EPS
-2.69
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Sep 30, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant achievements in collaborative and strategic partnerships, financial stability, and progress in R&D. However, there were challenges related to decreased income, increased net loss from an associated venture, and limited cash for unpartnered programs.
Company Guidance
In the Addex Therapeutics Half Year 2025 Financial Results call, the company reported substantial progress in its GABAB PAM program, particularly highlighting the completion of IND-enabling studies in partnership with Indivior for a substance use disorders drug candidate. Under this agreement, Addex is eligible for up to USD 330 million in payments upon achieving specific milestones, alongside tiered royalties. They also regained rights to their mGlu2 positive allosteric modulator program from Johnson & Johnson and are exploring new therapeutic indications. Financially, Addex ended the first half of 2025 with CHF 2.3 million in cash, projecting a runway through mid-2026, although this does not cover advancing unpartnered programs into the clinic. Their R&D expenses decreased to CHF 0.2 million, reflecting the completion of certain research phases. Addex is also advancing its independent GABAB PAM program for chronic cough, with preclinical studies showing promising efficacy and tolerability. The company is actively seeking financing to initiate IND-enabling studies for this program.
Successful Completion of IND-Enabling Studies
Indivior completed IND-enabling studies for a GABAB PAM drug candidate for substance use disorders, a key milestone in their partnership.
Regained Rights to mGlu2 Program
Addex regained rights to the mGlu2 positive allosteric modulator program, including the Phase II asset ADX71149, from Johnson & Johnson.
Investment in Stalicla
Invested in Stalicla, a neurodevelopmental disorder-focused company, which has developed a precision medicine platform for patient stratification.
Financial Stability
Completed the half year with CHF 2.3 million in cash, providing a runway through mid-2026.
Reduced Cash Burn
Cash burn significantly reduced following the Neurosterix spin-out transaction.

Addex Therapeutics (ADXN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ADXN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 10, 2025
2025 (Q3)
- / -
-2.685
Sep 30, 2025
2025 (Q2)
- / -3.02
-2.685-12.33% (-0.33)
Jun 19, 2025
2025 (Q1)
- / -
-1.345
Apr 25, 2025
2024 (Q4)
- / -2.00
-1.345-48.70% (-0.66)
Nov 22, 2024
2024 (Q3)
- / -
-4.115
Sep 30, 2024
2024 (Q2)
-1.42 / -2.69
-4.11534.75% (+1.43)
Jun 06, 2024
2024 (Q1)
- / -
-5.367
Apr 18, 2024
2023 (Q4)
- / -1.34
-5.36774.94% (+4.02)
Nov 29, 2023
2023 (Q3)
-0.66 / -4.12
11.418-136.04% (-15.53)
Aug 10, 2023
2023 (Q2)
- / -5.49
-23.89177.00% (+18.40)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ADXN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Sep 30, 2025
$9.00$9.46+5.11%
Apr 25, 2025
$7.58$8.16+7.65%
Nov 22, 2024
$8.11$7.53-7.15%
Sep 30, 2024
$9.05$9.77+7.96%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Addex Therapeutics (ADXN) report earnings?
Addex Therapeutics (ADXN) is schdueled to report earning on Nov 10, 2025, TBA (Confirmed).
    What is Addex Therapeutics (ADXN) earnings time?
    Addex Therapeutics (ADXN) earnings time is at Nov 10, 2025, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ADXN EPS forecast?
          Currently, no data Available
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis